期刊
CLINICS IN LIVER DISEASE
卷 13, 期 3, 页码 453-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2009.05.001
关键词
Hepatitis C; Polymerase inhibitors; Antiviral therapy; Clinical trials; Nucleoside analog; Non-nucleoside analog
Chronic hepatitis C virus (HCV) infection affects approximately 4 million persons and is the major indication for liver transplantation in the United States. The current standard for treatment of HCV is pegylated interferon in combination with ribavirin. Despite significant advances in treatment, only approximately 50% of patients of treated patients clear HCV infection. Polymerase inhibitors, given their potent antiviral effects, represent a major contribution to the future of HCV treatment. Whether these new drugs will have a role in the treatment of the difficult patient (non-responders, those co-infected with HIV, decompensated liver disease and liver transplant recipients) remains to be determined.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据